Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting As Acute Lymphoblastic Leukemia

Overview

Journal Case Rep Hematol

Publisher Wiley

Specialty Hematology

Date 2012 Oct 20

PMID 23082258

Citations 10

Authors

Karl Haslam

Stephen E Langabeer

Johanna Kelly

Natasha Coen

Niamh M OConnell

Eibhlin Conneally

Affiliations

Soon will be listed here.

Abstract

Hematopoietic myeloproliferative neoplasms (MPNS) with rearrangements of the receptor tyrosine kinase FGFR1 gene, located on chromosome 8p11, are uncommon and associated with diverse presentations such as atypical chronic myeloid leukemia, acute myeloid leukemia, or an acute T- or B-lymphoblastic leukemia, reflecting the hematopoietic stem cell origin of the disease. A review of MPN patients with the t(8;22) translocation that results in a chimeric BCR-FGFR1 fusion gene reveals that this disease either presents or rapidly transforms into an acute leukemia that is generally unresponsive to currently available chemotherapeutic regimens including tyrosine kinase inhibitors (TKIS). The first case of a rare BCR-FGFR1 MPN presenting in a B-acute lymphoblastic phase who underwent allogeneic hematopoietic stem cell transplantation (HSCT) with a subsequent sustained complete molecular remission is described. Allogeneic HSCT is currently the only available therapy capable of achieving long-term remission in BCR-FGFR1 MPN patients.

Citing Articles

Hematological Neoplasms with Eosinophilia.

Morales-Camacho R, Caballero-Velazquez T, Borrero J, Bernal R, Prats-Martin C Cancers (Basel). 2024; 16(2).

PMID: 38254826 PMC: 10814743. DOI: 10.3390/cancers16020337.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

Metzgeroth G, Steiner L, Naumann N, Lubke J, Kreil S, Fabarius A Leukemia. 2023; 37(9):1860-1867.

PMID: 37454239 PMC: 10457188. DOI: 10.1038/s41375-023-01958-1.

Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12).

Nakamura F, Seo S, Nannya Y, Ayabe R, Takahashi W, Handa T Int J Hematol. 2023; 118(3):388-393.

PMID: 36930401 PMC: 10415475. DOI: 10.1007/s12185-023-03577-z.

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.

Cowell J, Hu T Cancer Drug Resist. 2021; 4:607-619.

PMID: 34734169 PMC: 8562765. DOI: 10.20517/cdr.2021.30.

Functional characterization of two rare BCR-FGFR1 leukemias.

Barnes E, Leonard J, Medeiros B, Druker B, Tognon C Cold Spring Harb Mol Case Stud. 2020; 6(2).

PMID: 31980503 PMC: 7133745. DOI: 10.1101/mcs.a004838.

References

Lee S, Park T, Lee S, Lee K, Song J, Kim J . Rare translocations involving chromosome band 8p11 in myeloid neoplasms. Cancer Genet Cytogenet. 2008; 186(2):127-9. DOI: 10.1016/j.cancergencyto.2008.07.002. View

Demiroglu A, Steer E, Heath C, Taylor K, Bentley M, Allen S . The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001; 98(13):3778-83. DOI: 10.1182/blood.v98.13.3778. View

Murati A, Arnoulet C, Lafage-Pochitaloff M, Adelaide J, Derre M, Slama B . Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. Int J Oncol. 2005; 26(6):1485-92. View

Chase A, Bryant C, Score J, Cross N . Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica. 2012; 98(1):103-6. PMC: 3533670. DOI: 10.3324/haematol.2012.066407. View

Qureshi A, Mitchell C, Richards S, Vora A, Goulden N . Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010; 149(3):410-3. DOI: 10.1111/j.1365-2141.2010.08132.x. View

Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billstrom R, Isaksson M . Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer. 2001; 32(4):302-10. DOI: 10.1002/gcc.1195. View

Chase A, Grand F, Cross N . Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007; 110(10):3729-34. DOI: 10.1182/blood-2007-02-074286. View

Chen J, DeAngelo D, Kutok J, Williams I, Lee B, Wadleigh M . PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004; 101(40):14479-84. PMC: 521956. DOI: 10.1073/pnas.0404438101. View

Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P . The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 2011; 96(6):922-6. PMC: 3105656. DOI: 10.3324/haematol.2010.036558. View

10.

van Dongen J, Macintyre E, Gabert J, Delabesse E, Rossi V, Saglio G . Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13(12):1901-28. DOI: 10.1038/sj.leu.2401592. View

11.

Agerstam H, Lilljebjorn H, Lassen C, Swedin A, Richter J, Vandenberghe P . Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer. 2007; 46(7):635-43. DOI: 10.1002/gcc.20442. View

12.

Suzan F, Guasch G, Terre C, Garcia I, Bastie J, Maarek O . Long-term complete haematological and molecular remission after allogeneic bone marrow transplantation in a patient with a stem cell myeloproliferative disorder associated with t(8;13)(p12;q12). Br J Haematol. 2003; 121(2):312-4. DOI: 10.1046/j.1365-2141.2003.04269.x. View

13.

Ren M, Tidwell J, Sharma S, Cowell J . Acute progression of BCR-FGFR1 induced murine B-lympho/myeloproliferative disorder suggests involvement of lineages at the pro-B cell stage. PLoS One. 2012; 7(6):e38265. PMC: 3368885. DOI: 10.1371/journal.pone.0038265. View

14.

Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P . Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012; 26(7):1693-5. DOI: 10.1038/leu.2012.8. View

15.

McCann S, Crampe M, Molloy K, Lawler M . Hemopoietic chimerism following stem cell transplantation. Transfus Apher Sci. 2005; 32(1):55-61. DOI: 10.1016/j.transci.2004.10.006. View

16.

Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010; 120(7):2254-64. PMC: 2898591. DOI: 10.1172/JCI41246. View

17.

Townsend W, Cross N, Waghorn K, Somana K, Ramsay A, Thomson K . Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder. Bone Marrow Transplant. 2009; 44(3):197-9. DOI: 10.1038/bmt.2008.448. View

18.

Pini M, Gottardi E, Scaravaglio P, Giugliano E, Libener R, Baraldi A . A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. Hematol J. 2003; 3(6):315-6. DOI: 10.1038/sj.thj.6200201. View

19.

Patnaik M, Gangat N, Knudson R, Keefe J, Hanson C, Pardanani A . Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. Am J Hematol. 2010; 85(4):238-42. DOI: 10.1002/ajh.21631. View

20.

Richebourg S, Theisen O, Plantier I, Parry A, Soenen-Cornu V, Lepelley P . Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes Cancer. 2008; 47(10):915-8. DOI: 10.1002/gcc.20588. View